1. Home
  2. COYA
  3. COYA News

Latest Coya Therapeutics Inc. (COYA) News on September 13, 2025

iAccess Alpha's Virtual Best Ideas Summer Investment Conference June 24-25, 2025
COYA

ACCESS Newswire

3 months ago

iAccess Alpha's Virtual Best Ideas Summer Investment Conference June 24-25, 2025

COYA

Business Wire

3 months ago

Coya Therapeutics to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24 – 25, 2025

COYA

Business Wire

3 months ago

Coya Therapeutics Announces Issuance of New U.S. Patent Protecting Methods of Producing Recombinant Human (rh) Interleukin-2 (aldesleukin) Liquid Formulations

Coya Therapeutics First Quarter 2025 Earnings: Misses Expectations
COYA

Simply Wall St.

4 months ago

Coya Therapeutics First Quarter 2025 Earnings: Misses Expectations

COYA

Business Wire

4 months ago

Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

COYA

Business Wire

4 months ago

Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update

COYA

Business Wire

4 months ago

Coya Therapeutics to Participate in Two Upcoming Conferences in May 2025

Is Coya Therapeutics, Inc. (COYA) Outperforming Other Medical Stocks This Year?
COYA

Zacks

4 months ago

Is Coya Therapeutics, Inc. (COYA) Outperforming Other Medical Stocks This Year?

COYA

Business Wire

5 months ago

Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia

Wall Street Analysts See a 144.73% Upside in Coya Therapeutics, Inc. (COYA): Can the Stock Really Move This High?
COYA

Zacks

5 months ago

Wall Street Analysts See a 144.73% Upside in Coya Therapeutics, Inc. (COYA): Can the Stock Really Move This High?

COYA

Business Wire

5 months ago

Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death)

Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program
COYA

GlobeNewswire

5 months ago

Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program

Is Coya Therapeutics (COYA) the Top Healthcare Stock to Buy According to Billionaire David Einhorn?
COYA

Insider Monkey

5 months ago

Is Coya Therapeutics (COYA) the Top Healthcare Stock to Buy According to Billionaire David Einhorn?

COYA

Business Wire

5 months ago

Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025

What Makes Coya Therapeutics, Inc. (COYA) a New Buy Stock
COYA

Zacks

6 months ago

What Makes Coya Therapeutics, Inc. (COYA) a New Buy Stock

Wall Street Analysts Think Coya Therapeutics, Inc. (COYA) Could Surge 149.62%: Read This Before Placing a Bet
COYA

Zacks

6 months ago

Wall Street Analysts Think Coya Therapeutics, Inc. (COYA) Could Surge 149.62%: Read This Before Placing a Bet

Are Medical Stocks Lagging Auna S.A. (AUNA) This Year?
COYA

Zacks

6 months ago

Are Medical Stocks Lagging Auna S.A. (AUNA) This Year?

COYA

Business Wire

6 months ago

Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program

Coya Therapeutics (NASDAQ:COYA) Is In A Good Position To Deliver On Growth Plans
COYA

Simply Wall St.

6 months ago

Coya Therapeutics (NASDAQ:COYA) Is In A Good Position To Deliver On Growth Plans

COYA

Business Wire

6 months ago

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results

COYA

Business Wire

7 months ago

Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer’s Disease Using GLP-1 Agonists and Combinations

Coya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly Dosing
COYA

Benzinga

7 months ago

Coya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly Dosing

COYA

Business Wire

7 months ago

Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer’s Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical Development

COYA

Business Wire

7 months ago

Coya Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

An ALS treatment wave is approaching, and this biotech CEO is ready to surf
COYA

Pharma Voice

8 months ago

An ALS treatment wave is approaching, and this biotech CEO is ready to surf

COYA

Business Wire

8 months ago

Coya Therapeutics Announces Pipeline Expansion - COYA 303: COYA 301 in Combination with GLP-1 Receptor Agonist for the Treatment of Inflammatory Diseases

EXCLUSIVE: Coya Therapeutics Expands Its Pipeline With Combo Therapy For Inflammatory Diseases
COYA

Benzinga

8 months ago

EXCLUSIVE: Coya Therapeutics Expands Its Pipeline With Combo Therapy For Inflammatory Diseases

COYA

Business Wire

9 months ago

Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD)

COYA

Business Wire

10 months ago

Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference

COYA

Business Wire

10 months ago

Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders

COYA

Business Wire

10 months ago

Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results

COYA

MT Newswires

10 months ago

Coya Therapeutics New CEO Arun Swaminathan Takes Helm

COYA

Business Wire

10 months ago

Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer

Coya Therapeutics Reports Positive Phase 2 Alzheimer’s Trial Results
COYA

TipRanks

10 months ago

Coya Therapeutics Reports Positive Phase 2 Alzheimer’s Trial Results

COYA

MT Newswires

10 months ago

Sector Update: Health Care Stocks Ease Late Afternoon

Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study
COYA

Benzinga

10 months ago

Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study

COYA

MT Newswires

10 months ago

Coya Therapeutics Shares Fall After Phase 2 Alzheimer's Disease Study Results

COYA

Business Wire

10 months ago

Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer’s Disease (AD) Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid (Spain)

COYA

Business Wire

a year ago

Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer’s Disease

COYA

Business Wire

a year ago

Coya Therapeutics Announces Closing of $10.0 Million Private Placement

COYA

Business Wire

a year ago

Coya Therapeutics Announces $10.0 Million Private Placement

COYA

Business Wire

a year ago

Coya Therapeutics Chairman and CEO Howard Berman Selected for PharmaVoice 100

COYA

Business Wire

a year ago

Coya Therapeutics to Participate in Fireside Chat at the Chardan 8th Annual Genetic Medicines Conference

COYA

Business Wire

a year ago

Coya Therapeutics Announces Subcutaneously Administered COYA 302 Elicits Direct Anti-Inflammatory Effect in Brain in a Preclinical Inflammatory Mouse Model of Parkinson’s Disease

Here's Why We're Not At All Concerned With Coya Therapeutics' (NASDAQ:COYA) Cash Burn Situation
COYA

Simply Wall St.

a year ago

Here's Why We're Not At All Concerned With Coya Therapeutics' (NASDAQ:COYA) Cash Burn Situation

COYA

Business Wire

a year ago

Coya Therapeutics to Present at Upcoming Healthcare Conferences

COYA

Business Wire

a year ago

Coya Therapeutics Promotes Arun Swaminathan Ph.D. to Chief Executive Officer Effective November 1st, 2024

COYA

Business Wire

a year ago

Coya Therapeutics Provides a Corporate Update and Reports Unaudited Second Quarter 2024 Financial Results

COYA

Business Wire

a year ago

Coya Therapeutics Announces that Results from a Double-Blind Placebo-Controlled Study in Alzheimer’s Disease will be presented on October 29, 2024 at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid

COYA

Business Wire

a year ago

Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents for COYA 301 in Combination with Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

COYA

Business Wire

a year ago

Coya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with Funding from the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform into the Clinic

Coya Therapeutics Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology
COYA

Business Wire

a year ago

Coya Therapeutics Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology

COYA

Business Wire

a year ago

Coya Therapeutics Announces Acceptance of Peer-Reviewed Manuscript in the Medical Journal: Frontiers in Neurology

COYA

Business Wire

a year ago

Coya Therapeutics Announces Inclusion in the MSCI USA Micro Cap Index

EXCLUSIVE: Coya Therapeutics, Focused On Neurodegenerative Diseases Has Gained 70% Since IPO; CEO Highlights Efforts On Combination Therapy For Rare Diseases
COYA

Benzinga

a year ago

EXCLUSIVE: Coya Therapeutics, Focused On Neurodegenerative Diseases Has Gained 70% Since IPO; CEO Highlights Efforts On Combination Therapy For Rare Diseases

Coya Therapeutics concludes Phase II Alzheimer’s therapy trial
COYA

Clinical Trials Arena

a year ago

Coya Therapeutics concludes Phase II Alzheimer’s therapy trial

COYA

Business Wire

a year ago

Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease

COYA

MT Newswires

a year ago

Coya Therapeutics Receives $5 Million Equity Investment from Alzheimer's Drug Discovery Foundation

COYA

Business Wire

a year ago

Coya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer’s Drug Discovery Foundation (ADDF)

Coya Therapeutics, Inc.'s (NASDAQ:COYA) largest shareholders are retail investors with 60% ownership, insiders own 16%
COYA

Simply Wall St.

a year ago

Coya Therapeutics, Inc.'s (NASDAQ:COYA) largest shareholders are retail investors with 60% ownership, insiders own 16%

COYA

GuruFocus.com

a year ago

Coya Therapeutics Reports First Quarter 2024 Financial Results

COYA

Business Wire

a year ago

Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results

COYA

Business Wire

a year ago

Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium

COYA

Business Wire

a year ago

Coya Therapeutics to Participate in the Mizuho Neuroscience Summit

COYA

Business Wire

a year ago

Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit

COYA

Business Wire

a year ago

Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium

We're Not Very Worried About Coya Therapeutics' (NASDAQ:COYA) Cash Burn Rate
COYA

Simply Wall St.

a year ago

We're Not Very Worried About Coya Therapeutics' (NASDAQ:COYA) Cash Burn Rate

COYA

GuruFocus.com

a year ago

Coya Therapeutics Inc (COYA) Reports Fiscal 2023 Financial Results and Corporate Updates

COYA

Business Wire

a year ago

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results

COYA

Business Wire

2 years ago

Coya Therapeutics to Participate in BTIG Fireside Discussion

COYA

Business Wire

2 years ago

Coya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference

COYA

Business Wire

2 years ago

Coya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in Frontotemporal Dementia (FTD) at the AD/PD 2024 Conference

COYA

Business Wire

2 years ago

Coya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 Conference

COYA

Business Wire

2 years ago

Coya Therapeutics to Present Novel Biomarker Survival Data in Large Cohort of ALS (Amyotrophic Lateral Sclerosis) Patients at Society of Neuroimmune Pharmacology Conference

COYA

Business Wire

2 years ago

Coya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer’s Disease and Coya’s Pathway to a "Pipeline in a Product"

COYA

Business Wire

2 years ago

Coya Therapeutics Licenses Intellectual Property Rights for Use of Next Generation Immune Modulatory Biologics in Combination with COYA 301 to Enhance Regulatory T Cells (Tregs) in Inflammatory Diseases

MiX Telematics Reports Third Quarter Fiscal Year 2024 U.S. GAAP Financial Results
COYA

Business Wire

2 years ago

MiX Telematics Reports Third Quarter Fiscal Year 2024 U.S. GAAP Financial Results

New Pacific Metals Announces 2024 Plans for Operations in Bolivia
COYA

PR Newswire

2 years ago

New Pacific Metals Announces 2024 Plans for Operations in Bolivia

Are Medical Stocks Lagging AlloVir (ALVR) This Year?
COYA

Zacks

2 years ago

Are Medical Stocks Lagging AlloVir (ALVR) This Year?

COYA

Business Wire

2 years ago

Coya Therapeutics SAB Chairman Dr. Stanley Appel, M.D. Selected as Speaker at the Society of Neuroimmune Pharmacology Conference

TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer
COYA

GlobeNewswire

2 years ago

TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer

Phunware Appoints Industry Veteran Elliot Han to its Board of Directors
COYA

GlobeNewswire

2 years ago

Phunware Appoints Industry Veteran Elliot Han to its Board of Directors

NaaS Technology's Full Portfolio of Charging Pile Products Obtained CE Certification from the European Union
COYA

PR Newswire

2 years ago

NaaS Technology's Full Portfolio of Charging Pile Products Obtained CE Certification from the European Union

Why QuickLogic (QUIK) Outpaced the Stock Market Today
COYA

Zacks

2 years ago

Why QuickLogic (QUIK) Outpaced the Stock Market Today

Standard Lithium Advances South West Arkansas Project: Definitive Feasibility Study and Front-End Engineering Design Firm Chosen
COYA

GlobeNewswire

2 years ago

Standard Lithium Advances South West Arkansas Project: Definitive Feasibility Study and Front-End Engineering Design Firm Chosen

Stewart Elected to Serve on the Head Office Board of Directors for the Federal Reserve Bank of San Francisco
COYA

GlobeNewswire

2 years ago

Stewart Elected to Serve on the Head Office Board of Directors for the Federal Reserve Bank of San Francisco

Elevation Oncology Announces Appointment of Darcy Mootz, Ph.D., to its Board of Directors
COYA

PR Newswire

2 years ago

Elevation Oncology Announces Appointment of Darcy Mootz, Ph.D., to its Board of Directors

COYA

Business Wire

2 years ago

Coya Therapeutics to Participate in Upcoming Chardan Biotech Leadership Call Series

Has Leidos (LDOS) Outpaced Other Aerospace Stocks This Year?
COYA

Zacks

2 years ago

Has Leidos (LDOS) Outpaced Other Aerospace Stocks This Year?

COYA

Business Wire

2 years ago

Coya Therapeutics Announces Pipeline Expansion of COYA 302 to Include Frontotemporal Dementia and Parkinson’s Disease in Addition to Amyotrophic Lateral Sclerosis

DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing
COYA

PR Newswire

2 years ago

DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing

IO Biotech, Inc. (NASDAQ:IOBT) most popular amongst private equity firms who own 61% of the shares, institutions hold 24%
COYA

Simply Wall St.

2 years ago

IO Biotech, Inc. (NASDAQ:IOBT) most popular amongst private equity firms who own 61% of the shares, institutions hold 24%

Built In Honors Terran Orbital in Its Esteemed 2024 Best Places To Work Awards
COYA

Business Wire

2 years ago

Built In Honors Terran Orbital in Its Esteemed 2024 Best Places To Work Awards

Valens Semiconductor and Intel Foundry Services Announce Strategic Relationship for Next Generation A-PHY Product
COYA

PR Newswire

2 years ago

Valens Semiconductor and Intel Foundry Services Announce Strategic Relationship for Next Generation A-PHY Product

COYA

Business Wire

2 years ago

Coya Therapeutics Announces Successful Pre-IND and Type C Meetings with the FDA to Advance the Development of COYA 302 for Treatment of Amyotrophic Lateral Sclerosis (ALS)

COYA

Business Wire

2 years ago

MFS Announces Closed-End Fund Distributions

H World Group Limited Announces the Change of Officers
COYA

GlobeNewswire

2 years ago

H World Group Limited Announces the Change of Officers

NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND ANNOUNCES MONTHLY DISTRIBUTION
COYA

PR Newswire

2 years ago

NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND ANNOUNCES MONTHLY DISTRIBUTION

Syntec Optics Launches Innovative Thermal Clip-On Scope (Nasdaq: OPTX)
COYA

GlobeNewswire

2 years ago

Syntec Optics Launches Innovative Thermal Clip-On Scope (Nasdaq: OPTX)

COYA

Business Wire

2 years ago

Mr. Wilbur L. Ross, Former United States Secretary of Commerce, Joins Board of Coya Therapeutics, Inc.

Share on Social Networks: